Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalating Study of CD19/CD22/BCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed/Refractory Multiple Myeloma

NCT06732232 is registered in ClinicalTrials.gov with Shanghai Cell Therapy Group Co.,Ltd as lead sponsor.

NCT NCT06732232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06732232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalating Study of CD19/CD22/BCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Shanghai Cell Therapy Group Co.,Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
December 12, 2024
Completion date
December 12, 2027
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, refractory, relapsed